Effect of MRA on Cardiovascular Disease in Patients With Hypertension and Hyperaldosteronemia
A phase 4 trial registered on ClinicalTrials.gov. The registry status is enrolling by invitation. It plans to enroll 8000 participants.
Also called NCT05688579
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose prevention
- Phase
- Phase 4
- Enrolled
- 8,000 participants
- Sponsor
- Nanfang Li
- Registry
-
NCT05688579
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Enrolling by invitation
Technical summary
Registry record NCT05688579. Randomized; single masking; primary purpose prevention. Start 2023-04-16 (actual); primary completion 2026-12-31 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Effect of MRA on Cardiovascular Disease in Patients With Hypertension and Hyperaldosteronemia
- Acronym
- EMRACHH
- Condition
- Hypertension
- Condition
- Hyperaldosteronaemia
- Intervention (Drug)
- Mineralocorticoid Receptor Antagonists(MRAs)
- Intervention (Other)
- Blank control
- Lead sponsor
- Nanfang Li
Record details
- Record id
cardio:ct-nct05688579- Content hash
1b3bbd6984457a0247cbb4a4cbc53d430b29f98f28fc2b358eaeaf27c3631aef